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Abstract
Background: The World Health Organization Framework Convention for Tobacco Control (FCTC) established the
MPOWER policy package to provide practical country-level guidance on implementing effective policies to reduce
smoking rates. The Abridged SimSmoke tobacco control policy simulation model is applied to Israel to estimate the
effects on reducing smoking-attributable mortality resulting from full implementation of MPOWER policies.
Methods: Smoking prevalence from the 2014 Israel National Health Interview Survey 3 and population data from
the Israel Central Bureau of Statistics were used to calculate the number of current smokers. The status of current
Israeli policy was determined using information from MPOWER 2015 and from local sources. Based on existing
knowledge that between 50 % and 65 % of smokers will die prematurely from smoking, the model is used to
determine mortality reductions among current smokers from full implementation of MPOWER policies.
Results: We estimate that between 550 and 710 thousand smokers of the current 1.1 million Israeli smokers will
prematurely die due to smoking. Within 40 years, complete implementation of MPOWER policies is projected to
reduce smoking prevalence among current smokers by 34 % and avert between 188 and 245 thousand deaths
among current smokers. Taxes, smoke-free air laws, marketing restrictions and media campaigns each reduce
smoking by about 5 % within 5 years. Improved cessation treatment and health warnings each have smaller
effects in the next five years, but their effects grow rapidly over time.
Conclusions: Israel Abridged SimSmoke shows that complete implementation of the MPOWER strategies has the
potential to substantially reduce smoking prevalence, and avert premature deaths due to smoking. Additional
benefits are also expected from reduced morbidity, reduced initiation among nonsmokers, and reduction in
exposure of nonsmokers to tobacco smoke.
Abbreviations: FCTC, Framework convention for tobacco control; MPOWER, WHO package to implement the
FCTC; WHO, World Health Organization
Background
To reduce non-communicable deaths, the World Health
Organization (WHO) set a voluntary target of a 30 %
reduction in smoking rates by 2025 as part of its global
Non-Communicable Disease agenda [1]. In addition, the
WHO launched a policy package that focuses on selected
demand side measures for tobacco products, MPOWER,
in 2008 [2]. This package recommends the following
policies: Monitor tobacco use and prevention policies,
Protect people from tobacco smoke, Offer help to quit
tobacco use, Warn about the dangers of tobacco, Enforce
bans on tobacco advertising, promotion and sponsorship,
and Raise taxes on tobacco. The magnitude of the effect
of each MPOWER policy on smoking prevalence varies
and depends on the policies implemented, how they are
implemented, and the country-level policies that were
previously in effect [3].
The Simsmoke Tobacco Control Policy simulation model
has been used to estimate the impact of past policies and
potential impact of implementing stronger MPOWER
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policies on smoking prevalence and smoking-attributable
deaths among current smokers within a country or state
[4–10]. This model projects the smoking rates over time
with the birth and deaths, and the initiation and cessation
of smokers. The model predicts well by age and gender
for countries that have and have not implemented many
strong policies [5–11]. In a previous application [10], we
developed a simplified form of SimSmoke, Abridged
SimSmoke, to evaluate the results of implementing past
MPOWER-required policies on country-level reductions
in smoking-related deaths. A later paper [12] extended
Abridged SimSmoke to show the effect of implementing
future policies in accordance with MPOWER require-
ments. The model calculates the impact of the policies on
current smokers only, and does not address those who
have not yet begun smoking.
The data requirements for Abridged SimSmoke are less
than for the original SimSmoke and parallel the smoking
prevalence and policy data collected for the biennial
WHO MPOWER/WHO Report on the Global Tobacco
Epidemic [1]. Like SimSmoke, Abridged SimSmoke pro-
jects changes in smoking prevalence and smoking-
attributable deaths resulting from the implementation
of MPOWER policies. We apply that model to Israel.
Israel ratified the FCTC in August 2005 (apps.who.int/
fctc/implementation/database/parties/Israel) [13]. Pre-
viously, Israel had implemented multiple tobacco poli-
cies including taxation (beginning in 1952 and since
expanded), smoke-free air policies (beginning in 1982
and since expanded), restrictions on advertising (begin-
ning in 1983 and since expanded), and health warnings
(beginning in 1983 and since expanded). Since signing
the FCTC, Israel has legislated and implemented stronger
smoke-free air laws and began to subsidize cessation treat-
ment through the National Basket of Services. However,
despite the passage of the National Plan for Reduction of
Smoking and its Harms in 2011, which was based in part
on the FCTC and MPOWER, Israel does not yet meet the
complete MPOWER requirements for any of the six
recommended MPOWER policies [13, 14]. For example,
smoke-free regulations are not well enforced [13, 15–20]
he planned comprehensive ban on advertising, promotion,
and marketing did not pass into legislation, and there is
no targeted budget for media campaigns or other tobacco
control activities [13].
In this paper, we present the results of the Abridged
SimSmoke applied to Israel. We estimate the effects of
implementing the policies meeting the FCTC-MPOWER
requirements on smoking prevalence and smoking-
attributable deaths among current smokers in Israel.
Methods
Abridged SimSmoke uses data from a single year to project
short-term (5 years) and long-term (40 years) effects on
smoking prevalence. It is similar to the original SimSmoke
in that it relies on population size smoking prevalence and
policy modules to make predictions. Abridged SimSmoke
also uses formulas similar to SimSmoke to show a re-
duction in smoking prevalence in each policy module.
Therefore, Abridged SimSmoke predicts the effect of in-
dividual and combined policies on smoking prevalence
and the number of smokers, which is used to project
the number of smoking-attributable deaths among smokers
alive in 2014.
Smokers and smoking-attributable deaths
First, the number of smokers, by gender, is obtained by
multiplying the respective smoking prevalence and the
corresponding population size. Population data for 2014
is from Table 2.5 of the Israel Central Bureau of Statistics.
Smoking prevalence (ages 20 and above) is from the most
recent nationally representative survey, the 2014 Israel
National Interview Health Survey 3, with sample size 2774
[21]. The weighted prevalence rate of smokers was 24.5 %
for men and 13.2 % for women.
The number of deaths attributable to smoking is deter-
mined using a formula based on the relative risks of
smoking. Doll et al [22] concluded that “half of all regu-
lar cigarette smokers will eventually be killed by their
habit”. Recent studies [23, 24] found that about 65 %,
rather than half, of current smoker deaths are attribut-
able to smoking. Upper and lower estimates of deaths
expected are calculated by applying the estimates of 50 %
and 65 %, respectively. Applying the relevant policy effect
sizes, we calculate the expected reduction in smokers and
deaths as result of a specific policy or group of policies.
Policy levels and effect sizes
Abridged SimSmoke uses SimSmoke policy effect size esti-
mates, which are based on literature reviews, the advice of
expert panels, and model validation [4, 5, 10, 25, 26]. For
each policy, the effect size, is applied as a percentage re-
duction in smoking prevalence. An urban adjustor, mea-
sured as [1 % employed in agriculture], and the percent
not in the labor force, are applied to the work-site effect
size, to reflect that smoke-free work-site laws primarily in-
fluence the population who work indoors. Israel had 2 %
of workers in agriculture [27] and a labor participation
rate of 60 % for women and 70 % for men [28].
Based on SimSmoke, a long-term multiplier is esti-
mated for each policy as the ratio of the relative change
in prevalence (after 40 years) to the relative change in
short-term prevalence (after 5 years). This method is
applied to the MPOWER policies. These policies are
described and their effect sizes listed in Table 1, with
upper and lower bound ranges provided in terms of per-
centage increases and reductions in effect size.
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Table 1 Policies, specifications and effect sizes used in abridged SimSmoke








Tax as a percent of retail
price of cigarettes
Excise tax, taking into
account expanded effect
through value added tax
5.9 % (with price elasticity -0.15c
and tax as a percent of price
increasing from 69 % to 75 %)
(-25 %- + 25 %) 2 no
Smoke-free air laws
Ban in all indoor
workplaces
Ban in all indoor private
workplaces
6 % (-50 %, +50 %) 1.25 yes
Ban in indoor offices only Ban except ventilated
workplaces
4 % (-50 %, +50 %) 1.25 yes
Ban in health facilities, univ,
govt. facilities (2 of 3)
Ban in work areas only 2 % (-50 %, +50 %) 1.25 yes
Restaurants: Smoke-free
in all indoor areas
Ban in restaurants 2 % (-50 %, +50 %) 1.25 yes
Pubs and bars: smoke-free Ban in pubs and bars 1 % (-50 %, +50 %) 1.25 yes
Enforcement MPOWER: 0-10 25 % of effect depends on
% enforcement (of 10)
Publicity Based on level of tobacco
control funding
25 % of above effect
depends on publicity




≥ $0.50 USD per capita &
media campaign
6.5 % reduction (-50 %, +50 %) 1.2 no
Moderately publicized campaign Tobacco control spending
≥ $0.05 and < $0.50 USD
per capita
3.5 % reduction (-50 %, +50 %) 1.2 no
Low publicized campaign If tobacco control spending
< $0.05 USD per capita
1.0 % reduction (-50 %, +50 %) 1.2 no
Marketing Bansd
Ban on direct and indirect
marketing
Ban on all direct and indirect
advertising
5 % (-50 %, +50 %) 1.3 no
Ban on advertising Ban on all direct advertising 3 % (-50 %, +50 %) 1.3 no
Partial ban on advertising Ban on some direct or
indirect advertising
1 % (-50 %, +50 %) 1.3 no
Enforcement MPOWER: 0 – 1.0 50 % of effect depends
on enforcement
Health Warningsd
Complete Bold and graphic, covers
50 % of package
2 % (-50 %, +50 %) 2 no
Strong Warning 30–50 % of package 1 % (-50 %, +50 %) 2 no




If sold by pharmacy or general
store and if Rx required
Prev. reduced 0.667 % if
available at w/out Rx,
0.334 % if Rx
(-75 %, +75 %) 2.5 yes
Bupropion and Varenicline Sold by pharmacy with
prescription
Prev. reduced 0.334 %, (-75 %, +75 %) 2.5 yes
Provision of treatments Type facilities: primary care,
hospitals, health professionals,
community and other
If provided in in most,
prevalence reduced 2.25 %,
if provided in some,
then 1.125 %
(-75 %, +75 %) 2.5 yes
Levy et al. Israel Journal of Health Policy Research  (2016) 5:41 Page 3 of 10
The effect of implementing stronger policies depends
on the initial level of policies. For example, the effect of
further marketing restrictions (e.g., in compliance with
MPOWER) will be less for a country that already has ex-
tensive restrictions than for a country without any mar-
keting restrictions. Data on the level of each policy is from
the most recent MPOWER reports [1] and Rosen [13].
Three types of smoke-free air policies (as applied to
worksites, restaurants and bars, and other public places)
are included in Abridged SimSmoke, with the effect of
worksite bans further distinguished by their stringency:
1) partial, as designated by a ban in 2 of the 3 following
types of facilities: health, university, and government
facilities, 2) a ban in indoor offices only, and 3) a ban in
all indoor workplaces. The effects are halved in the ab-
sence of publicity (based on tobacco control campaign
spending as described below) and complete enforcement
(an index based on MPOWER reports from 1 to 10,
where 10 = complete enforcement). Smoke-free legisla-
tion in public places was first introduced in Israel at the
national level in 1982 and was expanded over the years
to include public transportation, cinemas, theatres, educa-
tional institutions, and workplaces, among others; how-
ever, the only places to be mandated as 100 % smoke-free
were health-care facilities. In 2007, smoke-free legislation
(P) shifted from restriction to prevention, with increasing
fines and liabilities for owners. In 2012, the ban was ex-
tended to youth centers, nursing homes, religious institu-
tions, all government buildings, and some outdoor
public areas [13]. Rather than 100 % smoke-free work-
places, smoking is permitted in private offices in non-
governmental buildings. In addition, bars, and pubs are
permitted to set aside a quarter of their space for
smokers as long as it is in a separate room. There are
fines for violations on the establishment owners and pa-
trons, but they are inconsistently enforced. When citizen
complaints are registered, investigations are undergone
but are, likewise, inconsistent in scope and regularity. In
Dec. 2015, a new regulation was passed in the Knesset
which stipulated that all schools be entirely smoke-free,
effective in January 2016. The level of restrictions is set at
50 % for worksites, restaurants and bars and other pub-
lic places, and compliance is set at level 3 out of 10 in
the MPOWER Reports, as it is a well-known problem
[19, 20, 29, 30].
MPOWER cessation treatment has three sub-policies:
pharmacotherapy (PT) availability, financial coverage of
treatments, and quit lines. Quit lines reflect the presence
of a national quit line. Israel does not have a national
quit line, however, two of its four HMOs have quit lines,
and the Israel Cancer Association provides information
by telephone. In 2010, smoking cessation technologies
were added to the National Basket of Services. Free
smoking cessation workshops were made available and
Varencline, and Zyban became subsidized, contingent
on attendance at the cessation workshops. Nicotine
Replacement Therapy, (NRT) which has been available
over the counter, was added in 2015 as a second-line
medication, in case a smoker was unable to use Varenicline
or Zyban. Attempts to add individual and phone coun-
seling have been unsuccessful [13].
Health warnings on packs has four policy levels: none,
minimal (<30 % of the principal display area of the pack),
moderate (a warning covering at least 30 % of the princi-
pal display area of the pack, and meets 1 to 7 of the seven
pack warning criteria), and complete (a warning that
covers at least 50 % of the principal display pack area and
includes all seven pack warning criteria, including
graphic warnings, as well as a ban on deceitful terms).
According to the 2014 MPOWER Report, Israel has a
moderate policy, as the warning covers 30 % of the
principal display area of the pack and meets several
pack warning criteria. In addition to health warnings,
MPOWER includes media campaigns as an education
policy. SimSmoke rates media campaigns based on the
existence of a media campaign and funding levels speci-
fied for tobacco control. MPOWER reports do not
report expenditures for Israel, but indicate no national
campaign. Further, there is currently no dedicated
budget for tobacco control [13]. With few staff devoted
Table 1 Policies, specifications and effect sizes used in abridged SimSmoke (Continued)
Quit line type Operating active quit line Prev. reduced 0.5 % (-75 %, +75 %) 2.5 yes
Overall effect With all of the above policies
and publicity based on
tobacco control funding
Prev. reduced 4.75 %,
25 % of effect depends
on publicity
(-75 %, +75 %) 2.5 yes
Notes: HIC high-income country, LIC low-income country, MIC middle-income country, NA not applicable, NRT nicotine replacement therapy
aShort-term effect size is defined as the relative percentage change in smoking prevalence in first five years of policy implementation. The long-term effect is
short-term-effect multiplied by the long-term multiplier, adjusted by awareness and urban status adjustors. We also provide ranges for the effect sizes, which are
measured as percentage variation in the effect sizes compared to the level in the preceding column
bThe urban adjustor reduces the effect to reflect the percentage of the rural population not affected by the policies indicated
cSee Levy et al [32] for a description of the calculations
dCategories are mutually exclusive categories
eEffects are additive over policies
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to tobacco control, media campaigns are categorized as
at a low level.
Four levels of marketing restriction policies are desig-
nated: none, minimal, moderate, and comprehensive re-
strictions. They include restrictions on advertising as well
as marketing practices, such as branding and sponsorship.
For marketing restrictions, no enforcement will reduce the
impact of the policy by half. According to the MPOWER
Report, Israel has a minimal policy for marketing restric-
tions, as two out of eight areas are bans on direct adver-
tising and three out of fifteen are bans on indirect
advertising, ranked 2 out of 4 (minimal). For direct ad-
vertising, Israel has a ban on national TV and radio and
fines for violating this ban, but does not have bans on
magazines and newspapers, billboards and outdoor ad-
vertising, point of sale advertising, and the internet. For
bans on indirect advertising, Israel has bans on free distri-
bution in mail or through other means, appearance of to-
bacco brands in TV and/or film (product placement) and
fines for violating these bans, but does not ban promo-
tional discounts, non-tobacco goods or services identified
with tobacco brand names, brand names of non-tobacco
goods or services used for tobacco products, appearance
of tobacco products in TV and/or films, sponsored events,
display at point of sale, bans on the tobacco or other
industries publicizing their activities, bans on tobacco
companies funding or making contributions to smoking
prevention media campaigns including those directed
at youth, and a requirement to present prescribed anti-
tobacco ads before, during, or after the broadcasting or
showing of any visual entertainment. According to the
MPOWER reports, Israel has advertising restrictions
ranked as level 2 out of 4 in the MPOWER Reports.
Compliance is at level two of 10.
Cigarette taxation affects cigarette price which, in turn,
influences cigarette use. Taxes are specified as a percent
of the retail cigarette price. In accordance with MPOWER
policies, we consider the effect of increasing excise taxes
(including ad valorem taxes or specific (per unit) taxes
directly on cigarettes) to 75 % of price. The value added
tax (VAT) applies to all goods, not just cigarettes, but amp-
lifies the effect of an excise tax on cigarette price. The
change in excise taxes is first translated into the implied
percentage change in price. The prevalence elasticity is
applied to the percentage change in price to obtain the
percent change in prevalence. In Israel, a pack of ciga-
rettes is 30.00 NIS (7.80 USD), of which 17 % is value
added (since October 2015) and 69.03 % is excise taxes.
There was an increase of over 10 % in cigarette taxes in
Israel between 2002 and 2013 [16]. Incorporating the
percentage increase in taxes [t/(1 + t)] as amplified
through the effect of value added taxes, an increase in
taxes from 69 % to 75 % is predicted to increase
cigarette prices by 39 %.
The effect of combined policies is calculated with all
policies reaching their MPOWER targets. The effects are
proportionally reduced for each additional policy. Thereby,
relatively conservative assumptions are made about the ef-
fects of combined policies (e.g., some overlapping effects),
and the overall effect is bounded between zero and one.
However, synergies are built into the model through
media campaigns that enhance the effect of smoke-free
air laws and cessation treatment policies.
Results
The results are presented in Table 2. The table first pre-
sents the initial levels for smoking prevalence (by gender)
and the total number of smokers. Based on the current
level of smoking (24.5 % among males and 13.2 %
among females), the number of smokers is 1.1 million
in 2014. Based on numbers of smokers, the number of
smoking-attributable deaths is projected as 550 thousand
(350 thousand male and 200 thousand female) as a lower
estimate and 710 thousand (455 thousand male and 255
thousand female) as an upper estimate of the smokers
alive in 2014.
The table also shows the effects of each policy indi-
vidually and in combination. The effects are projected as
short and long-term percentage reductions in smoking
prevalence and the long-term effects on the number of
smokers and smoking-attributable deaths.
 Increasing excise cigarette taxes from its current
level of 69 % to 75 % of price will reduce male and
female smoking prevalence by 5.9 % within 5 years,
increasing to 11.7 % in 40 years, and will avert
between 64 and 83 thousand premature deaths.
 Comprehensive smoke-free air laws that made all
worksites, restaurants, bars and other public places
smoke-free along with stronger enforcement will
reduce male and female smoking prevalence by 4.6 %
in five years, increasing to 5.8 % in 40 years, and will
avert between 32 and 41 thousand premature deaths.
 A well-publicized, comprehensive cessation policy
that included a national quitline along with financial
full coverage of all treatments will reduce smoking
prevalence by 2.6 % in 5 years, increasing 6.5 % in
40 years, and will avert between 35.5 and 46 thousand
premature deaths.
 A high level media campaign will reduce smoking
prevalence by 5.5 % in 5 years, increasing to 6.6 % in
40 years, and will avert between 36 and 47 thousand
premature deaths.
 Pictorial health warnings that cover 50 % of the
cigarette package will reduce smoking prevalence
by 2 % in 5 years, increasing to 4 % in 40 years,
and will prevent between 22 and 28 thousand
premature deaths.
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Table 2 Policy effects by MPOWER policy, individual and total: Israel
Current levels Smoking prevalence Number of smokers Projected deaths of smokers (lower) Projected deaths of smokers (upper)
Male Female Male Female Total Male Female Total







Reduction in smoking attributable
deaths (lower)
Reduction in smoking attributable
deaths (upper)
Male Female Total Male Female Total
Protect through Smoke-free Air Laws
Moderate -4.6 % -5.8 % 63,403 20,270 11,431 31,702 26,352 14,860 41,212
Offer Cessation Treatments
Moderate -2.6 % -6.5 % 70,918 22,673 12,786 35,459 29,475 16,622 46,097
Mass Media Campaigns
Low -5.5 % -6.6 % 72,144 23,065 13,007 36,072 29,984 16,909 46,893
Warnings on Cigarette Packages
Moderate -2.0 % -4.0 % 43,724 13,979 7,883 21,862 18,172 10,248 28,420
Enforcement of Marketing Restrictions
Low-moderate -4.4 % -5.7 % 62,525 19,990 11,273 31,262 25,986 14,655 40,641
Raise Cigarette Taxes
Excise Tax 69 % -5.9 % -11.7 % 127,969 40,913 23,072 63,984 26,593 14,997 83,180
Combined Policies
-22.6 % -34.3 % 374,408 119,701 67,503 187,204 155,611 87,754 243,365
Notes:
Short-term and long-term effect size are measured in terms of the percentage reduction in smoking prevalence from the initial pre-policy level, i.e., (Post-policy smoking prevalence - Pre-policy smoking prevalence)/
Pre-policy smoking prevalence. Lower and upper bounds for the long-term effect size and the reduction in smoking-attributable deaths can be obtained using the ranges for sensitivity analysis from provided
in Table 1













 A well-enforced comprehensive ban of direct and
indirect advertising (including tobacco products)
will reduce smoking prevalence by 4.4 % in 5 years,
increasing to 5.7 % in 40 years, and will prevent
between 31 and 41 thousand premature deaths.
With the stronger set of policies consistent with FCTC
recommendation as specified in MPOWER, the model
projects that smoking prevalence can be reduced by 23 %
within 5 years increasing to 34 % within 40 years. As a re-
sult, between 187 thousand (120 thousand male and 67
thousand female) and 240 thousand (157 thousand male
and 88 thousand female) premature deaths of current
smokers alive in 2015 are projected to be averted.
Discussion
Among smokers alive in 2014 in Israel, between 550 and
710 thousand premature deaths are predicted. This
demonstrates the urgent need for strong policies to
reduce tobacco use. Abridged Simsmoke provides esti-
mates of reductions in smoking prevalence, and the re-
sultant number of smoking-attributable deaths which
would be avoided, if MPOWER policies were fully im-
plemented [12]. With a complete implementation of
policies, Israel is predicted to reach the goal of reducing
smoking rates by 22 % in the next 5 years and by 34 %
in forty years. As a consequence, between 187 thousand
and 243 thousand premature deaths will be averted.
The model indicates that increased cigarette taxes, stronger
and better enforced smoke-free air laws, and media cam-
paigns and marketing restrictions can play an important
role. To a lesser extent, bolder and graphic health warnings
and more comprehensive provision of cessation treatments
will also contribute to decreasing the burden of tobacco-
related mortality.
Abridged SimSmoke has been developed based on an
extensively validated simulation model and provides sup-
port for our estimates. To explicitly consider the predic-
tions of the abridged model, we have compared predictions
from Abridged SimSmoke for nine countries that have
reached MPOWER goals, including Finland and Italy, to
results from the complete SimSmoke model for or those
countries and found that the results predicted by Abridged
SimSmoke for smoking prevalence and deaths were rea-
sonably close to the reported findings from the com-
plete model [10]. Nevertheless, the findings from Abridged
SimSmoke should be interpreted in light of the model’s
limitations.
Abridged SimSmoke does not incorporate future changes
in demographics or smoking prevalence that may reflect
the effect of previously implemented policies. The abridged
model utilizes smoking prevalence data from 2014 as the
basis for estimates of the number of smokers and expected
deaths due to smoking among current smokers. The model
only attempts to incorporate the effects of stronger future
policies on those who were smokers in that survey year. It
does not incorporate changes in smoking trends, including
those that may be influenced by changes in policies im-
plemented prior to that year, or by smoking cessation
which may occur spontaneously over time, as indicated
by patterns of declining smoking prevalence among
older adults [21].
Difference in smoking patterns between the Jewish and
Arab population (Age adjusted estimates: Jewish males:
23.1 %, Jewish females: 14.0 %, Arab males: 46.6.%, Arab
females: 6.1 %) [21] are not addressed, due to a lack of suf-
ficient information to distinguish differences in relative
risks and differences in policy effects among these popula-
tions. Further research is warranted.
The model does not incorporate the effects of the un-
born, youth, and young adults who will initiate smoking
in future years (in the absence of strong policies). There-
fore, failure to incorporate cessation of current smokers
may be offset by the benefits of newly implemented
policies on reducing future initiation. While not considered
in our analysis, substantial additional gains can be expected
through the effects of policies on the young. In particular,
SimSmoke attributes more than twice the effect of tax in-
creases on those under the age of 24 as for those ages 25
and above [31, 32]. Further, advertising restrictions are ex-
pected to have a 50 % greater effect on those below age 24
[3, 33]. The implementation and enforcement of bans on
all smoking in the workplace can also be expected to have
an important impact on those newly entering the work-
force. These estimates would imply a 25–35 % overall
reduction in smoking initiation. We estimate between
550,000 and 710,000 deaths due to smoking. Ginsburg
and Geva [34, 35] estimated the number of smoking-
attributable deaths at 7,400 per year, implying about
375,000 deaths over 50 years. However, there are import-
ant differences between the two methods (e.g., Ginsburg
and Geva used deaths by cause vs our use of total mortal-
ity, and our upper level estimates are based on higher
levels of risks found in the more recent studies [23, 24]).
Further study is warranted to examine the composition of
deaths by cause and the number of deaths over time by
age and gender. In addition, we focused on mortality, but
additional costs are associated with morbidity and prod-
uctivity loss due to premature death. In addition to the
7000 and 7850 smoking-attributable deaths each year,
Ginsburg and Geva [34, 35] estimated 319,231 active and
356,601 total smoking attributable hospital days and 1678
million NIS ($482 million) in total health service costs, 0.2
% of GNP. With productivity losses, smoke related costs
overall were 3,587 million NIS ($1,030 million), 0.41 % of
GNP. We did not include deaths due to second hand-
smoke in the model. Globally, secondhand smoke is re-
sponsible for 1 % of total mortality and 0.7 % of the
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worldwide disease burden [36]. We also did not address
the economic costs or pain and suffering, caused by to-
bacco smoke exposure, such as increases in rates of
child respiratory disease, low birthweight, sudden infant
death syndrome, and pre-term birth [37]. A study of
parentally-reported exposure of infants aged 0–2 between
2009–2012 found that 31.5 % (Jewish infants: 24.8 %, Arab
infants: 52.0) of infants were at least occasionally exposed
to tobacco smoke [21]. A reduction in smoking rates
would also decrease exposure of children to smoking.
Another limitation is that the effect of policies is subject
to uncertainty. We have provided ranges of the effect sizes
in Table 1. In addition, the model only applies to cigarettes
and thus does not incorporate other tobacco products
such as pipes, cigars, water pipes, and smokeless tobacco.
If tax increases and other policies target cigarette smokers
exclusively, there may be a substitution toward greater
usage of other tobacco products. By directing policies
(e.g., media campaigns) at all tobacco products, some of
this substitution may be avoided. E-cigarettes potentially
provide a lower harm alternative to smoking and therefore
may either accelerate or attenuate reductions in net
population smoking prevalence depending on how they
influence smoking patterns (e.g, initiation and cessation
rates) and related policies and practices [38].
Abridged SimSmoke has been developed to use data
from the biennial WHO MPOWER Reports. The
MPOWER policy data are restricted to a specific set of
policies and definitions. The model does not consider
policies directed at price minimizing behavior [39],
enforcement against smuggling [40], product regulation
(e.g., nicotine reduction) [41, 42], plain packaging [43, 44],
harm reduction policies (i.e., encouraging substitution of
less harmful alternatives to cigarettes) [45, 46] and youth
access policies [47]. These other policies have also been
shown to be effective and are likely to be needed for Israel
to approach the endgame for smoking cigarettes.
We did not consider the costs of the interventions
relative to their effectiveness. Studies of specific policies
have generally found that tobacco control policies are
cost effective [48–50]. Taxing policy and health warnings,
both of which involve minimal costs, are particularly cost
effective. Further study is warranted on the costs of imple-
mentation and the cost savings that would specifically be
incurred in Israel.
Abridged SimSmoke shows that the required MPOWER
tobacco control policies will save lives and eventually de-
crease tobacco use. The model enables the user to con-
sider policies individually and in combination to observe
how policies in different combinations lead to differing
rates of reductions in smoking prevalence and smoking-
attributable deaths. It also translates empirical information
into a user-friendly format that can be easily inter-
preted. This is particularly important given difficulties
inherent in tobacco-control policy making, which may
include local and global tobacco industry interference
[51, 52], lack of public knowledge of the harms of to-
bacco smoke exposure [12] and underestimation by
policy makers regarding public support for smoke-free
public places [29, 53].
Abridged SimSmoke for Israel shows an urgent need
for strengthening comprehensive and proven effective
policies and practices to combat and ultimately eliminate
the wholly preventable deaths and chronic disease bur-
dens and disabilities caused by tobacco use, primarily
driven by the smoking of cigarettes [54, 55].
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